For the quarter ending 2025-09-30, CDLX had -$2,784K decrease in cash & cash equivalents over the period. $1,747K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -72,673 | -22,565 |
| Credit loss expense | -51 | 1,833 |
| Depreciation and amortization | 6,473 | 12,566 |
| Amortization of financing costs charged to interest expense | 390 | 804 |
| Amortization of right-of-use assets | 515 | 1,274 |
| Gain on disposal or divestiture | -319 | 5,150 |
| Gain on debt extinguishment | 0 | 0 |
| Stock-based compensation expense | 6,422 | 16,195 |
| Impairment of goodwill and intangible assets | 58,843 | - |
| Change in contingent consideration | 0 | 102 |
| Other non-cash income, net | -1,825 | 8,076 |
| Accounts receivable | -4,643 | -10,165 |
| Prepaid expenses and other assets | -1,395 | 1,625 |
| Accounts payable | 1,644 | -1,837 |
| Other accrued expenses | 842 | 920 |
| Partner share liability | -5,007 | -5,913 |
| Consumer incentive liability | -3,819 | -4,174 |
| Net cash used in operating activities | 1,761 | -5,481 |
| Acquisition of property and equipment | 14 | 441 |
| Capitalized software development costs | 4,450 | 8,320 |
| Business divestiture and acquisitions, net of cash acquired | 0 | 200 |
| Net cash used in investing activities | -4,464 | -8,561 |
| Proceeds from issuance of debt | 50,000 | - |
| Settlement of contingent consideration | 0 | 5,000 |
| Principal payment of debt | 50,000 | 0 |
| Principal payments of 2020 convertible senior notes | - | 0 |
| Proceeds from termination of capped calls related to convertible notes | 0 | 0 |
| Proceeds from issuance of common stock | 0 | 0 |
| Proceeds from issuance of 2024 convertible senior notes | - | 0 |
| Equity issuance costs | 0 | 0 |
| Debt issuance costs | 12 | 93 |
| Net cash (used in) provided by financing activities | -12 | -5,093 |
| Effect of exchange rates on cash and cash equivalents | -69 | 286 |
| Net decrease in cash and cash equivalents | -2,784 | -18,849 |
| Cash and cash equivalents at beginning of period | 65,594 | - |
| Cash and cash equivalents at end of period | 43,961 | - |
Cardlytics, Inc. (CDLX)
Cardlytics, Inc. (CDLX)